Company intelligence / Profile preview

Anya Biopharm Inc.

Ownership: Private
Employees: ~24
Development stage: Phase 1

Overview

Anya Biopharm has developed the MIRA/JE® oral peptide formulation platform. Its lead product ANY002 is a GLP‑1 receptor agonist for type 2 diabetes and obesity that has completed early clinical pharmacokinetic studies in animals and humans. Another candidate (ANY004) is in preclinical development.[5] The company’s platform has demonstrated therapeutic delivery of several peptides across multiple studies.[1][3][6]

Therapeutic areas: Endocrinology
Modalities: Oral peptidesSmall molecules
Industry: Biotech

Drug pipeline

5 assets

ANY004X

4 more assets in the full pipeline.

Partnerships

Seeking collaborations with companies interested in oral delivery of their drugs via Mira/Je® platform. No specific partners named.

Beyond the preview

Go deeper on Anya Biopharm Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anya Biopharm Inc..